Celltrion (068270) Q1 2025 earnings summary

Executive summary

• Achieved 14.2% year-over-year revenue growth in 1Q25, reaching KRW 841.9 billion, driven by strong global adoption of Remsima SC, Yuflyma, and Vegzelma.

• Operating profit surged 870.1% year-over-year to KRW 149.4 billion, supported by completion of merger-related sales rights amortization and improved inventory and sales mix.

• Net income attributable to owners was KRW 108.7 billion, with basic EPS of KRW 530.

• Completed the merger with Celltrion Healthcare in December 2023, integrating development, production, and sales.

• Expanded direct sales channels in major markets, including the US and Europe, enhancing market presence.

Financial highlights

• 1Q25 consolidated sales: KRW 841.9B, up 14.2% year-over-year; operating profit: KRW 149.4B, up 870.1% year-over-year.

• Net profit for 1Q25: KRW 108.7B, net profit margin 12.9%.

• Gross profit margin improved to 52.6% in 1Q25 from 41.6% in 1Q24.

• Cash and cash equivalents at quarter-end were KRW 829.1B.

• COGS ratio improved significantly, aided by high-cost inventory depletion and higher sales of high-margin products.

Outlook and guidance

• 2025 sales forecast at KRW 5 trillion, representing over 40% year-over-year growth.

• Sales expected to be moderate in 1H25 and strong in 2H25, with new product launches further driving growth.

• Young portfolio projected to account for over 60% of total revenue in 2025.

• CDMO business expansion underway, with new subsidiary and facility investments planned.

• Ongoing pipeline development in ADCs, multi-specific antibodies, and global market expansion.